您的位置: 专家智库 > >

国家自然科学基金(30571940)

作品数:2 被引量:12H指数:2
相关作者:叶雪程洪艳崔恒成夜霞昌晓红更多>>
相关机构:北京大学更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 2篇中文期刊文章

领域

  • 2篇医药卫生

主题

  • 1篇独特型
  • 1篇移植瘤
  • 1篇特异
  • 1篇特异性
  • 1篇特异性免疫
  • 1篇细胞
  • 1篇细胞治疗
  • 1篇免疫
  • 1篇免疫细胞
  • 1篇免疫细胞治疗
  • 1篇抗独特型
  • 1篇抗独特型微抗...
  • 1篇抗体
  • 1篇OVARIA...
  • 1篇SKOV3细...
  • 1篇CIK
  • 1篇FUSION...
  • 1篇INDUCE...

机构

  • 1篇北京大学

作者

  • 1篇张果
  • 1篇郭慧方
  • 1篇付天云
  • 1篇张丽
  • 1篇昌晓红
  • 1篇成夜霞
  • 1篇崔恒
  • 1篇程洪艳
  • 1篇叶雪

传媒

  • 1篇癌症
  • 1篇Chines...

年份

  • 1篇2008
  • 1篇2006
2 条 记 录,以下是 1-2
排序方式:
Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice被引量:4
2006年
Background We have previously developed and characterized a monoclonal anti-idiotype antibody, designated 6B 11, which mimics an ovarian carcinoma associated antigen OC166-9 and whose corresponding monoclonal antibody is COC166-9 (Abl). In this study, we evaluate the humoral immune responses induced by the fusion protein 6B11 single-chain variable fragment (scFv)/human granulocyte macrophage colony-stimulating factor (hGM-CSF) and 6B 1 lscFv in BALB/c mice. Methods The fusion protein 6B 11 scFv/hGM-CSF was constructed by fusing a recombinant single-chain variable fragment of 6B11scFv to GM-CSE BALB/c mice were administrated by 6B11scFv/hGM-CSF and 6B11scFv, respectively. Results The fusion protein 6B11scFv/hGM-CSF retained binding to the anti-mouse F(ab)2' and was also biologically active as measured by proliferation of human GM-CSF dependent cell TF1 in vitro. After immunization with the 6B11scFv/hGM-CSF and 6BllScFv, BALB/c mice showed significantly enhanced Ab3 antibody responses to 6B11 scFv/hGM-CSF compared with the 6B11 scFv alone. The level of Ab3 was the highest after the first week and maintained for five weeks after the last immunization. Another booster was given when the Ab3 titer descended, and it would reach to the high level in a week. Conclusion The fusion protein 6B11scFv/hGM-CSF can induce humoral immunity against ovarian carcinoma in vivo. We also provide the theoretical foundation for the application of the fusion protein 6B11 scFv/hGM-CSF for active immunotherapy of ovarian cancer.
CHANG Xiao-hong YE Xue CUI Heng FENG Jie LI Yi ZHU Hong-lan YANG Wen-lan FU Tian-yun CHENG Hong-yan GUO Hui-fang
卵巢癌特异性免疫细胞治疗的体内外实验研究被引量:8
2008年
背景与目的:卵巢癌抗独特型微抗体(6B11mini)是部分人源化的抗独特型卵巢癌疫苗,体内外实验研究证明,它可以诱导出特异的抗卵巢癌体液免疫和细胞免疫。本研究评价将6B11mini作为抗原,采用免疫细胞的方法处理卵巢癌时的安全性和有效性。方法:用纯化的6B11mini负载树突细胞(dendritic cell,DC),与外周血单个核细胞(peripheral blood mononucleocyte,PBMNC)混合培养,在多种细胞因子共同作用下获得效应细胞6B11-OCIK。通过软琼脂克隆形成实验及接种裸鼠皮下瘤实验,观察6B11-OCIK在体内和体外的成瘤能力;将6B11-OCIK静脉注射BALB/c小鼠,观察急性毒性反应;体外Cr释放实验检测6B11-OCIK对靶细胞的杀伤作用。51用人卵巢癌细胞株SKOV3构建严重联合免疫缺陷(severe combined immune deficieney,SCID)小鼠卵巢癌移植瘤模型,注射6B11-OCIK,并以CIK、PBMNC细胞以及生理盐水作为对照组,分别观察各组肿瘤生长情况。结果:软琼脂培养14d,卵巢癌SKOV3细胞克隆形成良好,克隆形成率50%;皮下接种裸鼠后14d,阳性对照的宫颈癌HeLa细胞组全部成瘤,6B11-OCIK、CIK、WI-38组和新鲜PBMNC组持续观察13周没有成瘤。6B11-OCIK静脉注射BALB/c小鼠,30min内各剂量实验组和生理盐水对照组动物都无任何明显的不良反应;输注后第13天处死小鼠,解剖小鼠观察其各主要脏器无明显异常。在体外杀伤实验中6B11-OCIK对抗原阳性的肿瘤细胞具有特异性杀伤作用,并且与MHC限制性相关;在荷瘤SCID小鼠中6B11-OCIK治疗组肿瘤重量与生理盐水对照组相比差异有统计学意义(P=0.023),与CIK组、新鲜单采组相比差异无统计学意义(P=0.540,P=0.285)。结论:6B11-OCIK在动物体内应用时符合安全性指标,并对卵巢癌的生长有一定的抑制作用。
昌晓红程洪艳成夜霞叶雪郭慧方付天云张丽张果崔恒
关键词:抗独特型微抗体SKOV3细胞移植瘤CIK免疫细胞治疗
共1页<1>
聚类工具0